Pre-market: 1643.HK Modern Chinese Medicine (HKSE) -24.55% HK$1.26: forecasts

The 1643.HK stock plunged in pre-market trade, sliding 24.55% to HK$1.26 on heavy volume. Today’s move follows a gap lower from an open at HK$1.68, with intraday range HK$1.25–HK$2.00. Volume spiked to 16,026,000 shares, nearly ten times the average, signalling aggressive selling pressure ahead of Hong Kong trade.

1643.HK stock: pre-market plunge and key numbers

Modern Chinese Medicine Group Co., Ltd. (1643.HK) traded at HK$1.26 in pre-market action, down 24.55% from the prior close of HK$1.67. The stock opened at HK$1.68, has a year high of HK$2.00 and a year low of HK$0.25. Market capitalisation stands at HK$907.20M with 720,000,000 shares outstanding.

Trading, volume and liquidity for 1643.HK stock

Liquidity surged: volume hit 16,026,000 versus an average of 1,708,719, a relative volume of 9.48. This jump shows concentrated selling and creates execution risk for large orders. The 50-day average price is HK$0.91 and the 200-day average is HK$0.69, so short-term volatility is elevated.

Meyka AI rates 1643.HK with a score out of 100

Meyka AI rates 1643.HK with a score out of 100: 63.60, Grade B, Suggestion HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The company rating snapshot shows an A- style external rating with a Buy recommendation on 2026-03-10, highlighting mixed signals between fundamentals and momentum.

Valuation and key financials for 1643.HK stock

The stock trades at a trailing PE of 31.50 with EPS of HK$0.04. Price-to-book is 1.82 and cash per share is HK$0.47. Revenue per share is HK$0.34, and book value per share is HK$0.81. The company shows a strong current ratio of 8.53, indicating ample short-term liquidity.

Technicals and sector context for 1643.HK stock

Technicals show mixed signals: RSI 54.47 and ADX 59.94, indicating a strong directional move. Bollinger bands are HK$0.78–HK$1.64, so the pre-market price sits near the lower band. Healthcare peers trade at an average PE of 29.66, so 1643.HK’s PE of 31.50 is modestly richer than sector peers.

Risks, catalysts and near-term outlook for 1643.HK stock

Primary risks include earnings visibility and negative operating cash flow per share at -HK$0.01. The company declares no dividend. Catalysts would be a management update or stronger-than-expected sales to the elderly market. Watch for regulatory or product news that could change sentiment quickly.

Final Thoughts

The immediate takeaway for 1643.HK stock is a clear pre-market sell-off driven by volume and sentiment. With price at HK$1.26, market cap HK$907.20M, and a PE of 31.50, valuation sits slightly above healthcare peers. Meyka AI’s forecast model projects a 12-month level of HK$1.05, implying -17.04% from the current price, and a three-year target of HK$1.74, implying +37.81% upside. These projections show near-term downside risk but longer-term upside if growth resumes. Forecasts are model-based projections and not guarantees. Traders should monitor volume, any corporate updates, and healthcare sector moves before changing positions. Meyka AI, our AI-powered market analysis platform, flags liquidity and valuation as the key variables to watch.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.